Skip to content
U.S. Transhumanist Party – Official Website
  • Home
  • Posts
  • Values
  • Platform
  • Leadership
  • Advisors
  • Candidates
  • Highlights
  • FAQ
  • States & Allies
  • Free Membership
  • Facebook
  • Twitter
  • Search Icon

U.S. Transhumanist Party – Official Website

U.S. Transhumanist Party – PUTTING SCIENCE, HEALTH, & TECHNOLOGY AT THE FOREFRONT OF AMERICAN POLITICS

Alzheimer’s Drug Turns Back the Clock in Mitochondria – Article by Steve Hill

Alzheimer’s Drug Turns Back the Clock in Mitochondria – Article by Steve Hill

January 26, 2018 Steve Hill Comments 0 Comment

Steve Hill


Editor’s Note: In this article, Mr. Steve Hill discusses an experimental drug, J147, for treating Alzheimer’s disease and also how Alzheimer’s disease is closely linked to aging.  This article was originally published by the Life Extension Advocacy Foundation (LEAF).

                   ~ Kenneth Alum, Director of  Publication, U.S. Transhumanist Party, January 26, 2018

J147 is an experimental drug that has been shown to treat Alzheimer’s disease, and it also appears to reverse some aspects of aging. It is also poised to enter human clinical trials in the near future, although how it works has been somewhat of a puzzle.

A new study  published in the journal Aging Cell has changed all that, and the results are quite intriguing [1]. Researchers at the Salk Institute have solved the mystery of how J147 works and why it makes old flies, mice, and cells more youthful.

Rejuvenating mitochondria

The drug apparently works because it binds to a protein found in mitochondria, the powerhouses of cells; this, in turn, causes cells to function in a more youthful manner. Mitochondrial dysfunction is one of the hallmarks of aging and is thought to be a key reason why we age and develop age-related diseases [2]. This drug appears, at least partially, to address some of that dysfunction.

Finding the target of J147 was the key to revealing the link between Alzheimer’s disease and the aging process. It was the critical information the researchers needed and was holding the drug back from clinical trials.

Dave Schubert, head of Salk’s Cellular Neurobiology Laboratory, and his team originally developed the J147 drug in 2011. The team screened numerous plant-sourced compounds with the potential to reverse the cellular and molecular signs of aging in the brain. The drug was developed as a modified version of a molecule found in the spice curcumin, a common ingredient in Asian foods such as curry.

Since then, the researchers have shown that J147 can reverse memory deficits, increases the production of brain cells, and slows the progression of Alzheimer’s in mice [3]. However, at that point, they did not understand how J147 worked.

Finding the target

During the new study lead by Dave Schubert and Salk Research Associate Josh Goldberg, the researchers used a number of approaches to find out how J147 worked. They eventually identified that the target of J147 was the mitochondrial protein known as ATP synthase, specifically ATP5A, a subunit of that protein. ATP synthase is involved in the mitochondrial generation of ATP, which cells use for energy.

The researchers demonstrated that by reducing the activity of ATP synthase, they were able to protect neuronal cells from a number of toxicities associated with the aging of the brain. One reason for this neuroprotective effect is thought to be the role of excitotoxicity in neuronal cell damage.

Excitotoxicity is the pathological process by which neurons are damaged and killed by the overactivation of receptors for the excitatory neurotransmitter glutamate. Think of it being a bit like a light switch being turned on and off so rapidly that it ends up causing the light bulb to blow.

Recently, the role of ATP synthase inhibition for neuroprotection against excitotoxic damage was demonstrated in a mouse study [4]. The second study showed that mouse models expressing the human form of mutant ATPase inhibitory factor 1 (hIF1), which causes a sustained inhibition of ATP synthase, were more resilient to neuronal death after excitotoxic damage. This data is consistent with this new J147 study, in which an increase in IF1 in the mice reduced the activity of ATP synthase (specifically ATP5A) and was neuroprotective.

ATP synthase is implicated in aging

ATP synthase has previously been shown to influence aging in C. elegans worms and flies. Given that aging is the greatest risk factor for developing Alzheimer’s disease, it is no surprise that the target of the drug is also involved in the aging process.

The team also revealed that by modulating the activity of ATP synthase, they could influence the levels of ATP and other molecules and were able to encourage healthier, more stable mitochondria during aging. Mice given the compound showed profound changes, appearing to look younger at a cellular and molecular level.

The researchers believe that these results are not only encouraging for the treatment of Alzheimer’s, they suggest that J147 may also be useful in treating other age-related diseases.

“People have always thought that you need separate drugs for Alzheimer’s, Parkinson’s and stroke,” said Dave Schubert. “But it may be that by targeting aging we can treat or slow down many pathological conditions that are old-age-associated.”

With J147 having just completed the FDA required toxicology testing in animals, the next step is phase 1 human clinical trials, and the road to approval begins.

Conclusion

It is very heartening to hear important researchers suggesting that in order to treat age-related diseases, one needs to treat the aging processes themselves. This is the exactly what Dr. Aubrey de Grey and others have been saying for many years. It is good to hear more voices joining the call to tackle age-related diseases at their root: the hallmarks and damages where they all begin.

The process of age-related disease begins long before the familiar signs and diagnoses are made; by targeting the early processes that are not given specific disease names, we might yet defeat horrific diseases, such as Alzheimer’s, which rob us of who we are.

Literature

[1] Joshua Goldberg et al. The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell, 2018 DOI: 10.1111/acel.12715
[2] López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013). The hallmarks of aging. Cell, 153(6), 1194-1217.
[3] Prior, M., Dargusch, R., Ehren, J. L., Chiruta, C., & Schubert, D. (2013). The neurotrophic compound J147 reverses cognitive impairment in aged Alzheimer’s disease mice. Alzheimer’s research & therapy, 5(3), 25.
[4] Formentini, L., Pereira, M. P., Sánchez‐Cenizo, L., Santacatterina, F., Lucas, J. J., Navarro, C., … & Cuezva, J. M. (2014). In vivo inhibition of the mitochondrial H+‐ATP synthase in neurons promotes metabolic preconditioning. The EMBO journal, 33(7), 762-778.

About Steve Hill

As a scientific writer and a devoted advocate of healthy longevity technologies Steve has provided the community with multiple educational articles, interviews and podcasts, helping the general public to better understand aging and the means to modify its dynamics. His materials can be found at H+ Magazine, Longevity reporter, Psychology Today and Singularity Weblog. He is a co-author of the book “Aging Prevention for All” – a guide for the general public exploring evidence-based means to extend healthy life (in press).

About LIFE EXTENSION ADVOCACY FOUNDATION (LEAF)

In 2014, the Life Extension Advocacy Foundation was established as a 501(c)(3) non-profit organization dedicated to promoting increased healthy human lifespan through fiscally sponsoring longevity research projects and raising awareness regarding the societal benefits of life extension. In 2015 they launched Lifespan.io, the first nonprofit crowdfunding platform focused on the biomedical research of aging.

They believe that this will enable the general public to influence the pace of research directly. To date they have successfully supported four research projects aimed at investigating different processes of aging and developing therapies to treat age-related diseases.

The LEAF team organizes educational events, takes part in different public and scientific conferences, and actively engages with the public on social media in order to help disseminate this crucial information. They initiate public dialogue aimed at regulatory improvement in the fields related to rejuvenation biotechnology.


Guest Articles
aging, Alzheimer’s, ATP5A, ATPase inhibitory factor 1, Aubrey de Grey, Dave Schubert, diseases, Education, Excitotoxicity, FDA, hIF1, human clinical trials, J147, Josh Goldberg, LEAF, life extension, Life Extension Advocacy Foundation, longevity, mitochondria, mitochondrial ATP synthase, rejuvenation, research, Salk Institute, Steve Hill, technology

Post navigation

PREVIOUS
Exercise is Currently the Best Way to Slow Down Aging – Article by Michael Falk
NEXT
World Health Organization Puts the Elderly Back in the Picture – Article by Elena Milova

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Social Media

Constitution of the U.S. Transhumanist Party

Transhumanist Bill of Rights – Version 3.0

U.S. Transhumanist Party Facebook Feed

Free Transhumanist Symbols

Guidelines for Community Conduct

SUBMIT A POST

Subject Categories

    - Life Extension
    - Artificial Intelligence
    - Space Colonization
    - Robotics
    - Biotechnology
    - Nanotechnology
    - Autonomous Vehicles
    - 3D Printing
    - Cryptocurrencies
    - Vertical Farming
    - Universal Basic Income
    - Existential Risk
    - Rationality

Hashtags

    #USTranshumanistParty, #TranshumanistParty, #TranshumanistPolitics, #TomRoss2024, #RossTwedt2024

Recent Posts

  • The Copenhagen Consensus – How to Feed the Hungry – Article by Zach Richardson
  • The Issue of Food – Article by Luis Arroyo
  • Results of Platform Vote #9 and Vote on Proposals on Investigations and Emergency Declarations; Adopted Sections of the U.S. Transhumanist Party Constitution
  • Official Ballot Options for Platform Vote #9 and Proposals on Investigations and Emergency Declarations
  • Gennady Stolyarov I and Gennady Stolyarov II Discuss the Progress of Information Technology (2019)
  • Immortality: My Quest and Reasons for Seeking an Indefinite Lifespan – Article by Albi Ndoni
  • U.S. Transhumanist Party General Discussion Thread for 2025
  • U.S. Transhumanist Party Statement on the Murder of Brian Thompson
  • News Regarding THPedia, the Transhumanist Encyclopedia for Everyone – Invitation to Contribute – Statement by Gennady Stolyarov II
  • The Transhumanist Council: A Worthy Effort for a New Umbrella Transhumanist Organization
  • Report on the Montana Right to Try Act – Analysis by Shamar White
  • U.S. Transhumanist Party Comments on the Citizen Petition by Age Reversal Unity to Declare Aging a Disease
  • U.S. Transhumanist Party Chairman’s Eighth Anniversary Message
  • U.S. Transhumanist Party Statement on the Outcome of the 2024 U.S. Presidential Election
  • Preliminary Member-Reported Write-In Totals for Tom Ross and Daniel Twedt in the 2024 U.S. Presidential Election
  • U.S. Transhumanist Party and Nevada Transhumanist Party Positions on 2024 Nevada Ballot Questions
  • Where to Write In Tom Ross for President of the United States – and How to Make Sure Your Vote Counts
  • Celebration of U.S. Transhumanist Party 10th Anniversary and International Longevity Month
  • U.S. Transhumanist Party Virtual Enlightenment Salon with Tim Wass – June 23, 2024
  • How to Fight Homeopathy: Why People Believe in Homeopathy and What to Do with That – Article by Ariel VA Feinerman

Recent Comments

  • Gennady Stolyarov II on U.S. Transhumanist Party General Discussion Thread for 2025
  • Theo Ibrahim on The Issue of Food – Article by Luis Arroyo
  • Theo Ibrahim on U.S. Transhumanist Party General Discussion Thread for 2025
  • DTThompson on U.S. Transhumanist Party General Discussion Thread for 2025
  • R. Nicholas Starr on U.S. Transhumanist Party General Discussion Thread for 2025

Archives

  • March 2025 (3)
  • February 2025 (1)
  • January 2025 (3)
  • December 2024 (2)
  • November 2024 (6)
  • October 2024 (3)
  • September 2024 (2)
  • August 2024 (5)
  • July 2024 (4)
  • June 2024 (3)
  • May 2024 (1)
  • March 2024 (1)
  • February 2024 (1)
  • January 2024 (8)
  • October 2023 (11)
  • September 2023 (6)
  • August 2023 (1)
  • July 2023 (4)
  • May 2023 (3)
  • April 2023 (3)
  • March 2023 (2)
  • February 2023 (12)
  • January 2023 (23)
  • December 2022 (2)
  • November 2022 (2)
  • October 2022 (3)
  • August 2022 (3)
  • July 2022 (2)
  • May 2022 (6)
  • March 2022 (3)
  • February 2022 (4)
  • January 2022 (7)
  • December 2021 (11)
  • November 2021 (4)
  • October 2021 (5)
  • September 2021 (2)
  • August 2021 (2)
  • July 2021 (3)
  • June 2021 (2)
  • May 2021 (6)
  • April 2021 (7)
  • March 2021 (4)
  • February 2021 (5)
  • January 2021 (6)
  • December 2020 (10)
  • November 2020 (4)
  • October 2020 (2)
  • September 2020 (1)
  • August 2020 (4)
  • July 2020 (5)
  • June 2020 (6)
  • May 2020 (3)
  • April 2020 (3)
  • March 2020 (6)
  • February 2020 (1)
  • January 2020 (6)
  • December 2019 (3)
  • November 2019 (2)
  • October 2019 (9)
  • September 2019 (10)
  • August 2019 (12)
  • July 2019 (18)
  • June 2019 (17)
  • May 2019 (12)
  • April 2019 (8)
  • March 2019 (12)
  • February 2019 (7)
  • January 2019 (13)
  • December 2018 (9)
  • November 2018 (5)
  • October 2018 (9)
  • September 2018 (5)
  • August 2018 (10)
  • July 2018 (13)
  • June 2018 (14)
  • May 2018 (8)
  • April 2018 (8)
  • March 2018 (10)
  • February 2018 (15)
  • January 2018 (17)
  • December 2017 (8)
  • November 2017 (17)
  • October 2017 (19)
  • September 2017 (11)
  • August 2017 (11)
  • July 2017 (16)
  • June 2017 (15)
  • May 2017 (10)
  • April 2017 (7)
  • March 2017 (8)
  • February 2017 (16)
  • January 2017 (8)
  • December 2016 (6)
  • November 2016 (5)

Categories

  • Allied Projects
  • Announcements
  • Art
  • Candidates
  • Debate
  • Discussion Panels
  • Distributed Computing
  • Exposure Periods
  • Foreign Ambassadors
  • General Discussion
  • Guest Articles
  • Inclusion
  • Interviews
  • Legislative Analysis
  • Official Ballots
  • Petitions
  • Platform
  • Presentations
  • Press Releases
  • Research
  • Sample Ballots
  • Science Fiction
  • Statements
  • Tolerance
  • Virtual Enlightenment Salons
  • Vote Results
  • Working Groups

Victor Run Virtual Race – June 4-6, 2021

Historical Archive – 2020 U.S. Presidential Ticket – Charlie Kam and Liz Parrish

© 2025   Copyright - U.S. Transhumanist Party - All Rights Reserved | WordPress design: Art Ramon Paintings